The Food and Drug Administration plans on expediting CBD rules and regulations, potentially by the end of summer or early fall, according to Dr. Amy Abernathy, the principal deputy commissioner and acting chief information officer.

“We are enthusiastic about research into the therapeutic benefits of CBD products but also need to balance safety. To understand the breadth of issues and gather data on safety we have conducted a public hearing, reviewed the medical literature, and have an open public docket.” – Abernathy, viaTwitter

FDA Plans to Expedite CBD Regulations